M&A
Olon Continues its Growth Path and Announces a New Acquistion
Olon
PR-09-24-NI-01Sep 04, 2024
Developability
Assessing Developability and Designing Advanceable Formulations from the Start
Nazar Elkarim, Ph.D.
Mikart
PAO-09-24-CL-02Aug 26, 2024
Liquid Suspensions
Beyond Pills: the Rise of Liquid Suspensions for Complex Formulations
Gus LaBella
Mikart
PAO-07-24-CL-04Jul 09, 2024
Outsourced Manufacturing
A Closer Look at Small Molecule Drug Substance and Drug Product Manufacturing
April Stanley, MS MBA
Nice Insight
PAO-03-24-NI-02Mar 27, 2024
Nice Insight API Report
Small Molecule API Discovery and Development Trends
April Stanley, MS MBA
Nice Insight
PAO-03-24-NI-01Mar 21, 2024
Biomanufacturing
Antheia and Olon Continue Partnership for Biomanufacturing Antheia’s Pipeline of KSMs and APIs for Essential Medicines
Antheia
PR-M03-24-02Mar 13, 2024
High Potency API Suite
Expanding Capabilities for Clients:Olon to Open New High Potency API Suite in US
Olon
PR-M02-24-01Feb 05, 2024
Chromatography
Navigating HPLC Method Development: Tips for Success
Ransom Jones
Mikart
PAO-12-23-CL-09Jan 17, 2024
Process Chemistry
Enabling Client Success with Complementary Services Built upon a Strong Chemistry Foundation
Jean-Francois Vincent-Rocan, Ph.D.
BIOVECTRA
PAO-12-23-CL-02Dec 13, 2023
Is this Pharma’s Best Kept Secret? Partnering with Australian Companies for Pharmaceutical Development and Manufacturing
Grant Swart
Mayne Pharma Services
PAO-10-23-CL-04Oct 18, 2023
Modified-Release Drug Formulations
Simplifying Modified-Release Drug Formulations with High-Quality Multiparticulate Cores
Donald Loveday, Ph.D.; Bill McCarthy; Doug Hovey
SPI Pharma
PAO-05-23-CL-06Jun 06, 2023
Biocatalysis
Olon Presents the First Results Announcing to Have Achieved Developing A New Production Process Through Engineering Target Enzyme
Olon
PR-M05-23-02May 10, 2023
API
Enhanced Solubility through API Processing: Salt and Cocrystal Formation
Thomas Briel, Ph.D.; David Luedeker, Ph.D.
MilliporeSigma
PAO-05-23-CL-04May 05, 2023
HPAPIs
An Introduction to HPAPIs and Cytotoxic Drugs
Roots Analysis
PAO-04-23-CL-04Apr 25, 2023
New R&D Center
Addition of New U.S. R&D Center is the Next Step in Asymchem’s Globalization Strategy
Peng Dai, Ph.D.; Steven Hu, Ph.D.
Asymchem
PAO-02-23-CL-07Mar 09, 2023
Academic Research
Olon and The Chemistry Department of Politecnico University Launch a Research Project on Polymorphism and Characterization of API Solid State
Olon
PR-M02-23-02Feb 21, 2023
Parenteral Drug Products
Innovating to Optimize Quality in Injectable Drugs
Michael Howell
Grifols
PAO-11-022-CL-16Jan 12, 2023
Sustainable Manufacturing
Sustainability in Pharmaceutical Manufacturing: A CDMO’s Contribution
Mark McLaws, Ph.D.
Asymchem
PAO-11-022-CL-07Nov 22, 2022
Olon, International API Supplier, Releases New 2022 Sustainability Report
Olon
PR-M11-22-08Nov 22, 2022
Particle Engineering
Addressing Poor API Solubility with Comprehensive Particle Engineering Technology
Giorgio Bertolini, Ph.D.
Olon
PAO-11-022-CL-08Nov 18, 2022